ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Lineus Medical Obtains CE Mark for Flagship Product SafeBreak Vascular

By: PRLog
FAYETTEVILLE, Ark. - Sept. 30, 2025 - PRLog -- Lineus Medical has obtained CE Mark certification for its flagship product, SafeBreak® Vascular, the only breakaway device for IV lines clinically proven to reduce multiple IV complications.1 With this certification, SafeBreak Vascular is now cleared for use across the European Union. This approval expands SafeBreak Vascular's clearance from 5 countries to 32, spanning across more than three continents. Lineus Medical is actively partnering with distributors across Europe to expand hospital access to SafeBreak worldwide.

SafeBreak Vascular is a break-away device for IV lines clinically proven to reduce IV complications1. When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.

"Earning the CE Mark is a major milestone in our company's journey," says Vance Clement, CEO of Lineus Medical. "It reflects our commitment to remove the pains associated with IV lines and make SafeBreak Vascular the standard of care worldwide.  Our goal is to be the leading company in this market segment in both science and sales.  This clearance affirms that position and makes SafeBreak the first break-away device to have clearance in Asia, Europe, and North America."

Larry Hayes, VP of Sales comments, "With CE Mark approval, we are opening the door to new distribution partnerships across Europe. This certification allows SafeBreak Vascular to reach more hospitals and healthcare systems, accelerating our global commercialization strategy and expanding our global footprint."

"Achieving CE Mark certification is a testament to the quality and reliability of both our product and our manufacturing processes," said Will Armstrong, COO. "It reflects the strength of our team and our commitment to maintaining the highest standards."

About Lineus Medical
Lineus Medical is the developer of SafeBreak Vascular, a breakaway technology proven to reduce IV restarts and IV complications.1 Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn, Facebook, and Instagram.

References:
1.       Data on File

Photos: (Click photo to enlarge)

Lineus Medical Logo SafeBreak On Patient SafeBreak Vascular


Source: Lineus Medical

Read Full Story - Lineus Medical Obtains CE Mark for Flagship Product SafeBreak Vascular | More news from this source

Press release distribution by PRLog

Recent Quotes

View More
Symbol Price Change (%)
AMZN  220.69
+3.55 (1.63%)
AAPL  271.49
+5.24 (1.97%)
AMD  203.78
-2.24 (-1.09%)
BAC  51.56
+0.56 (1.10%)
GOOG  299.65
+9.67 (3.33%)
META  594.25
+5.10 (0.87%)
MSFT  472.12
-6.31 (-1.32%)
NVDA  178.88
-1.76 (-0.97%)
ORCL  198.76
-11.93 (-5.66%)
TSLA  391.09
-4.14 (-1.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.